Pharma major Zydus Lifesciences has announced significant updates to its ongoing share buyback program. The company's buyback committee approved an increase in the buyback price and a corresponding decrease in the total number of shares to be repurchased.
Revised Buyback Details
The revised buyback price has been set at Rs 1,260 per equity share, a notable increase from the previously announced price of Rs 1,150 per equity share. Concurrently, the maximum number of equity shares proposed to be bought back has been adjusted downwards from 95.65 lakh shares to 87.30 lakh shares. This revised quantity represents up to 0.87% of the company’s total paid-up equity share capital.
Zydus Lifesciences had initially announced its largest-ever share repurchase program on May 19, 2026. Under the original terms, the company intended to repurchase up to 95,65,217 shares, constituting 0.95% of its issued share capital, for a total outlay of Rs 1,100 crore at a price of Rs 1,150 per share.
Shareholder Eligibility and Intermediaries
The record date for determining eligible shareholders for the buyback remains May 29, 2026. Shareholders holding equity shares on this date are qualified to participate in the program.
ICICI Securities Ltd. is serving as the manager and registered broker for the buyback. MUFG Intime India Pvt. Ltd. has been appointed as the registrar for the process, ensuring smooth execution and shareholder communication.
“This has reference to our letters dated: (i) May 21, 2026, wherein we had submitted a copy of the public announcement dated May 20, 2026 which was published on May 21, 2026 (“Public Announcement”), in regard to the Buyback; and (ii) May 27, 2026, wherein we had informed you of an increase in the buyback price from INR 1,150/- [...] to INR 1,260/- [...] and a consequent reduction in the maximum number of Equity Shares proposed to be bought back by the Company from 95,65,217 [...] to 87,30,158 [...]” Zydus stated in its announcement.
This update reflects the company's dynamic approach to capital management and shareholder value, adjusting terms to market conditions and strategic considerations.